Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miriam Galbusera

Showing results (31-40 of 34) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 34 results.
Thrombosis and Haemostasis|September 28, 2006
In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpuraRoberta Donadelli, Federica Banterla, Miriam Galbusera, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 31, 2014
A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease modelsMarta Subías, Agustín Tortajada, Sara Gastoldi, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 11, 2019
An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic SyndromeMiriam Galbusera, Marina Noris, Sara Gastoldi, et al.
Plos One|December 20, 2021
Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort studyPiero Ruggenenti, Fabiano Di Marco, Monica Cortinovis, et al.
Pageof 4

Showing results (31-40 of 34) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 34 results.
Thrombosis and Haemostasis|September 28, 2006
In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpuraRoberta Donadelli, Federica Banterla, Miriam Galbusera, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 31, 2014
A novel antibody against human factor B that blocks formation of the C3bB proconvertase and inhibits complement activation in disease modelsMarta Subías, Agustín Tortajada, Sara Gastoldi, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|March 11, 2019
An Ex Vivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic SyndromeMiriam Galbusera, Marina Noris, Sara Gastoldi, et al.
Plos One|December 20, 2021
Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort studyPiero Ruggenenti, Fabiano Di Marco, Monica Cortinovis, et al.
Pageof 4